Active substance
Bezafibrate
- SFDA 2
- Health Canada 2
- NHS prices 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| BEZALIP 200MG TABS. | 200 mg | Tablet · Oral use | 50 Blister | SAR 20.70 | NCE · Prescription | ROCHE | Withdrawn by MAH · Not Marketed |
| BEZALIP RETARD 400MG TABS. | 400 mg | Tablet · Oral use | 30 Blister | SAR 31.20 | NCE · Prescription | ROCHE | Withdrawn by MAH · Not Marketed |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| BEZALIP SR | 02083523 | 400 MG | TABLET (EXTENDED-RELEASE) · ORAL | ALLERGAN INC |
| JAMP-BEZAFIBRATE SR | 02453312 | 400 MG | TABLET (EXTENDED-RELEASE) · ORAL | JAMP PHARMA CORPORATION |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Bezafibrate 200mg tablets | £9.05 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Bezafibrate 400mg modified-release tablets | £7.63 | 30 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.